Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 7c ; Offers Guidance
May 2, 2024 6:01 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.07), $0.07 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $47.07 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of... More
